The role of roxadustat in chronic kidney disease patients complicated with anemia
The incidence of chronic kidney disease (CKD) is increasing worldwide and the current prevalence rate is 13.4%. There are > 120 million CKD patients in China and this number is expected to increase. One of the main abnormalities in patients with CKD and kidney impairment is decreased synthesis of...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Association of Internal Medicine
2023-03-01
|
| Series: | The Korean Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://www.kjim.org/upload/kjim-2022-318.pdf |
| _version_ | 1811160714440605696 |
|---|---|
| author | Jie Liu Fan Yang Yousuf Waheed Shulin Li Kun Liu Xinglei Zhou |
| author_facet | Jie Liu Fan Yang Yousuf Waheed Shulin Li Kun Liu Xinglei Zhou |
| author_sort | Jie Liu |
| collection | DOAJ |
| description | The incidence of chronic kidney disease (CKD) is increasing worldwide and the current prevalence rate is 13.4%. There are > 120 million CKD patients in China and this number is expected to increase. One of the main abnormalities in patients with CKD and kidney impairment is decreased synthesis of erythropoietin (EPO), which causes anemia and affects iron metabolism. The probability of developing is higher in anemia patients with CKD than in the general population, and the incidence increases as kidney function decreases. Deficient EPO production by the kidney is the most important cause of renal anemia. Notably, anemia in patients with CKD has multiple causes, such as bleeding caused by platelet dysfunction, iron deficiency due to digestive and absorption disorders of the gastrointestinal tract, and shorter red blood cell life. Anemia is also a leading cause of hospitalization in patients with CKD. A new oral medication to treat renal anemia, the hypoxia-inducible factor prolyl hydroxylase inhibitor called roxadustat (FG-4592), regulates iron metabolism and promotes erythropoiesis. This drug has a therapeutic effect on patients with CKD. Roxadustat showed advantages over EPO in clinical experiments. This review summarizes the mechanisms of action, clinical applications, effectiveness, and safety of roxadustat. |
| first_indexed | 2024-04-10T06:03:09Z |
| format | Article |
| id | doaj.art-cc3d21e0bf8247a499a2c01c46e5d69e |
| institution | Directory Open Access Journal |
| issn | 1226-3303 2005-6648 |
| language | English |
| last_indexed | 2024-04-10T06:03:09Z |
| publishDate | 2023-03-01 |
| publisher | The Korean Association of Internal Medicine |
| record_format | Article |
| series | The Korean Journal of Internal Medicine |
| spelling | doaj.art-cc3d21e0bf8247a499a2c01c46e5d69e2023-03-03T07:00:11ZengThe Korean Association of Internal MedicineThe Korean Journal of Internal Medicine1226-33032005-66482023-03-0138214715610.3904/kjim.2022.318170763The role of roxadustat in chronic kidney disease patients complicated with anemiaJie Liu0Fan Yang1Yousuf Waheed2Shulin Li3Kun Liu4Xinglei Zhou5 Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China Department of Nephrology, Beijing Aerospace General Hospital, Beijing, China Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, ChinaThe incidence of chronic kidney disease (CKD) is increasing worldwide and the current prevalence rate is 13.4%. There are > 120 million CKD patients in China and this number is expected to increase. One of the main abnormalities in patients with CKD and kidney impairment is decreased synthesis of erythropoietin (EPO), which causes anemia and affects iron metabolism. The probability of developing is higher in anemia patients with CKD than in the general population, and the incidence increases as kidney function decreases. Deficient EPO production by the kidney is the most important cause of renal anemia. Notably, anemia in patients with CKD has multiple causes, such as bleeding caused by platelet dysfunction, iron deficiency due to digestive and absorption disorders of the gastrointestinal tract, and shorter red blood cell life. Anemia is also a leading cause of hospitalization in patients with CKD. A new oral medication to treat renal anemia, the hypoxia-inducible factor prolyl hydroxylase inhibitor called roxadustat (FG-4592), regulates iron metabolism and promotes erythropoiesis. This drug has a therapeutic effect on patients with CKD. Roxadustat showed advantages over EPO in clinical experiments. This review summarizes the mechanisms of action, clinical applications, effectiveness, and safety of roxadustat.http://www.kjim.org/upload/kjim-2022-318.pdfroxadustathypoxia-inducible factor inhibitoranemiarenal insufficiencychronicdialysis |
| spellingShingle | Jie Liu Fan Yang Yousuf Waheed Shulin Li Kun Liu Xinglei Zhou The role of roxadustat in chronic kidney disease patients complicated with anemia The Korean Journal of Internal Medicine roxadustat hypoxia-inducible factor inhibitor anemia renal insufficiency chronic dialysis |
| title | The role of roxadustat in chronic kidney disease patients complicated with anemia |
| title_full | The role of roxadustat in chronic kidney disease patients complicated with anemia |
| title_fullStr | The role of roxadustat in chronic kidney disease patients complicated with anemia |
| title_full_unstemmed | The role of roxadustat in chronic kidney disease patients complicated with anemia |
| title_short | The role of roxadustat in chronic kidney disease patients complicated with anemia |
| title_sort | role of roxadustat in chronic kidney disease patients complicated with anemia |
| topic | roxadustat hypoxia-inducible factor inhibitor anemia renal insufficiency chronic dialysis |
| url | http://www.kjim.org/upload/kjim-2022-318.pdf |
| work_keys_str_mv | AT jieliu theroleofroxadustatinchronickidneydiseasepatientscomplicatedwithanemia AT fanyang theroleofroxadustatinchronickidneydiseasepatientscomplicatedwithanemia AT yousufwaheed theroleofroxadustatinchronickidneydiseasepatientscomplicatedwithanemia AT shulinli theroleofroxadustatinchronickidneydiseasepatientscomplicatedwithanemia AT kunliu theroleofroxadustatinchronickidneydiseasepatientscomplicatedwithanemia AT xingleizhou theroleofroxadustatinchronickidneydiseasepatientscomplicatedwithanemia AT jieliu roleofroxadustatinchronickidneydiseasepatientscomplicatedwithanemia AT fanyang roleofroxadustatinchronickidneydiseasepatientscomplicatedwithanemia AT yousufwaheed roleofroxadustatinchronickidneydiseasepatientscomplicatedwithanemia AT shulinli roleofroxadustatinchronickidneydiseasepatientscomplicatedwithanemia AT kunliu roleofroxadustatinchronickidneydiseasepatientscomplicatedwithanemia AT xingleizhou roleofroxadustatinchronickidneydiseasepatientscomplicatedwithanemia |